The role of macrophages in pancreatic cancer: A new resistance mechanism revealed?

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), represents one of the deadliest forms of cancer. Despite scientific advances, the five-year survival rate remains alarmingly low, often below 10%. This aggressiveness is largely attributed to the tumor microenvironment (TME), which not only influences tumor growth but also its resistance to treatments. Macrophages, key players in innate immunity, play an ambiguous role within the TME. Often seen as accomplices in tumor progression, they can also act as active resistors against tumors.